Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedNo substantive content changes detected. The page appears the same aside from minor visual/layout adjustments.SummaryDifference0.1%

- Check10 days agoChange DetectedNo detectable content changes between the old and new screenshots; the study details, eligibility criteria, and outcomes sections appear consistent.SummaryDifference0.1%

- Check17 days agoChange DetectedThe page now shows a new document revision labeled v3.5.0 and removes the earlier v3.4.3 revision, indicating updated study documents are available.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedResults for the Phase I/II study of anti-CD3 x anti-HER2/Neu BATs with Pembrolizumab in metastatic breast cancer were posted, detailing dose-limiting toxicities, response rates, survival metrics, and immune monitoring data. Related study documents, including the Study Protocol and Informed Consent Form, were added.SummaryDifference3%

- Check53 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 on the page; there are no visible changes to the study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No user-visible changes to study details or page content.SummaryDifference0.1%

Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.